ORx Pharmaceutical Pipeline
GlycoBien®
INDICATION: Diabetes
GlycoBien® CR is a novel once-daily oral hypoglycemic drug for lowering blood sugar and reduction of glucose spikes. The drug product is designed to provide first-line therapy for both prediabetics and newly diagnosed type 2 diabetic patients. GlycoBien® CR is currently in Phase II clinical trial.